Next Article in Journal
Biomaterials for Soft Tissue Repair and Regeneration: A Focus on Italian Research in the Field
Next Article in Special Issue
Black Phosphorus, an Emerging Versatile Nanoplatform for Cancer Immunotherapy
Previous Article in Journal
Comprehensive Evidence of Carrier-Mediated Distribution of Amantadine to the Retina across the Blood–Retinal Barrier in Rats
Previous Article in Special Issue
Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies
 
 
Review

Nanoparticles to Target and Treat Macrophages: The Ockham’s Concept?

1
Department of Biomedicine, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
2
Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, CIBERehd, 08036 Barcelona, Spain
3
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Yogita Patil-Sen and Mohamed Elsawy
Pharmaceutics 2021, 13(9), 1340; https://doi.org/10.3390/pharmaceutics13091340
Received: 15 July 2021 / Revised: 15 August 2021 / Accepted: 19 August 2021 / Published: 26 August 2021
(This article belongs to the Special Issue Nanomaterials: Immunological Perspective)
Nanoparticles are nanomaterials with three external nanoscale dimensions and an average size ranging from 1 to 1000 nm. Nanoparticles have gained notoriety in technological advances due to their tunable physical, chemical, and biological characteristics. However, the administration of functionalized nanoparticles to living beings is still challenging due to the rapid detection and blood and tissue clearance by the mononuclear phagocytic system. The major exponent of this system is the macrophage. Regardless the nanomaterial composition, macrophages can detect and incorporate foreign bodies by phagocytosis. Therefore, the simplest explanation is that any injected nanoparticle will be probably taken up by macrophages. This explains, in part, the natural accumulation of most nanoparticles in the spleen, lymph nodes, and liver (the main organs of the mononuclear phagocytic system). For this reason, recent investigations are devoted to design nanoparticles for specific macrophage targeting in diseased tissues. The aim of this review is to describe current strategies for the design of nanoparticles to target macrophages and to modulate their immunological function involved in different diseases with special emphasis on chronic inflammation, tissue regeneration, and cancer. View Full-Text
Keywords: macrophages; nanoparticles; inflammation; cancer; regeneration macrophages; nanoparticles; inflammation; cancer; regeneration
Show Figures

Graphical abstract

MDPI and ACS Style

Medrano-Bosch, M.; Moreno-Lanceta, A.; Melgar-Lesmes, P. Nanoparticles to Target and Treat Macrophages: The Ockham’s Concept? Pharmaceutics 2021, 13, 1340. https://doi.org/10.3390/pharmaceutics13091340

AMA Style

Medrano-Bosch M, Moreno-Lanceta A, Melgar-Lesmes P. Nanoparticles to Target and Treat Macrophages: The Ockham’s Concept? Pharmaceutics. 2021; 13(9):1340. https://doi.org/10.3390/pharmaceutics13091340

Chicago/Turabian Style

Medrano-Bosch, Mireia, Alazne Moreno-Lanceta, and Pedro Melgar-Lesmes. 2021. "Nanoparticles to Target and Treat Macrophages: The Ockham’s Concept?" Pharmaceutics 13, no. 9: 1340. https://doi.org/10.3390/pharmaceutics13091340

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop